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10A wide range of diseases and conditions are monitored or diagnosed from blood
11plasma, but the ability to analyze a whole blood sample with the requirements for a
12point-of-care device, such as robustness, user-friendly, and simple handling,
13remains unmet. Microfluidics technology offers the possibility not only to work
14fresh thumb-pricked whole blood but also to maximize the amount of the obtained
15plasma from the initial sample and therefore the possibility to implement multiple
16tests in a single cartridge. The microfluidic design presented in this paper is a com-
17bination of cross-flow filtration with a reversible electroosmotic flow that prevents
18clogging at the filter entrance and maximizes the amount of separated plasma. The
19main advantage of this design is its efficiency, since from a small amount of sample
20(a single droplet 10 ll) almost 10% of this (approx 1 ll) is extracted and collected
21with high purity (more than 99%) in a reasonable time (5–8 min). To validate the
22quality and quantity of the separated plasma and to show its potential as a clinical
23tool, the microfluidic chip has been combined with lateral flow immunochromatog-
24raphy technology to perform a qualitative detection of the thyroid-stimulating hor-
25mone and a blood panel for measuring cardiac Troponin and Creatine Kinase MB.
26The results from the microfluidic system are comparable to previous commercial
27lateral flow assays that required more sample for implementing less tests. VC 2015
AIP Publishing LLC. [http://dx.doi.org/10.1063/1.4930865]
28I. INTRODUCTION
29Clinical blood tests are often used to determine or monitor diseases, mineral content, phar-
30maceutical drug effectiveness, and organ function. Multiple tests for specific blood components
31(such as a glucose test or a cholesterol test) are often grouped together into a blood panel.
32Although many researchers have developed plasma separation from whole blood utilizing dif-
33ferent techniques in microtechnologies, the volume of extracted plasma to implement the test is
34still one barrier to achieve a reliable miniaturized blood panel. Based on the recent microfluidic
35studies, particle separation methods and blood plasma extraction techniques could categorize in
36three main groups: centrifugal microfluidics (Lab-on-CD), paper-based microfluidics, and
37microfluidic chip.1AQ2 A centrifugal microfluidic system presents many advantages, but it needs to
38utilize intricate interconnects, specific equipment, and various valving systems (passive and
39active valves). The success of the blood plasma separation on the CD platform relies on these
40valving, additionally simple control of spinning speed of the motor for fluid handling on a CD
41platform has its own inherit limitations.2–4 Paper-based microfluidics or lab on a paper is an
a)Email: Mehdi.Mohammadi@dcu.ie
b)Author to whom correspondence should be addressed. Electronic mail: Jasmina.casals@upc.edu. Present address:
MicroTech Laboratory, Department of Mechanical Engineering, Technical University of Catalonia, Terrassa 08222,
Spain.
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42attractive microfluidic platform due to its low cost, ubiquitous, and compatibility with many
43medical and biochemical applications; however, it has some limitations such as sample reten-
44tion, need to control the fluid flow, rapidly clogging, and unable to analyze low concentrated
45analytes.5–8 Different approaches have been taken in the microfluidics chip format to achieve
46separation of plasma from whole blood, see the reviews.9–11
47The cross flow filtration method has demonstrated its outstanding properties to separate par-
48ticles from a suspension,12–15 but its major drawback is the clogging of the filtration area, which
49was solved either increasing the sample dilution12,13 or pumping at low flow rates.15 In our previ-
50ous work, Madadi et al.16 the blood plasma separation used cross-flow filtration and capillarity.
51But after a while, the blood flow velocity in the transport channel was slowed down, which leads
52to an accumulation of cells in the entrance of the separation area (red blood cells (RBCs) clog-
53ging), see Fig. 1(b) phenomena that limited the plasma extracted from a 5ll undiluted blood
54droplet (0.1ll). In this paper, to address this issue, an electric field is applied but during a limited
55time, which enables the extraction of up to 1ll from a 10ll droplet without RBCs lysis.
56Initially, most of the microfluidics chips and aforementioned cross flow filtration studies
57required a syringe pump to control the required flow rate to achieve plasma separation, which
58is not always available when thinking in a point-of-care (POC) device for blood testing near
59the patient and in general only few nanoliters of plasma could be separated. In most diagnostic
60procedures, plasma or serum (plasma deprived of clotting agents) must be extracted from full
61blood prior to analysis. Thus, the best opportunities for microfluidic POCT systems reside on
62those that provide separation of plasma from the components of blood and fulfill POC condi-
63tions such as short time to result, portability, flexibility, and low cost per test.17
64Electrokinetic (EK) technique has the potential to address these issues and create flow by
65utilizing a voltage difference that can be provided by a single on-board battery18 which elimi-
66nates the need of an external driving force. The use of electric fields for particle trapping and
67separation had been previously reported by researchers. For instance, Johann and Renaud com-
68bined electroosmotic and pressure-driven flow for particle sorting in multiple branched chan-
69nels.19 Kawamata et al. also used electroosmotic flow (EOF) for continuous particle separation
70in a design with multiple channels (two inlets and five outlets) and five electrodes to separate
71approximately 300 polystyrene particles.20 Wu et al. used hydrodynamic spreading, tuned by an
72electroosmotic flow in order to separate large E. coli cells, yeast cells, and fluorescent polysty-
73rene particles.21 In all these cases, the control of the applied voltage had to be very precise,20
74and most of them were not limited by the lysis of the cells. Nakashima et al. applied dielectro-
75phoresis to separate plasma from blood, but they limited the applied voltage to 10 AC Volts at
761 MHz. Using this configuration, they could separate 300 nl of plasma from a 5ll droplet.22
77Later, they increased the blood separation efficiency by increasing the applied voltage in
78expense of plasma contamination with lysed RBCs due to the generated high electric field.23
79The previous studies that employed EK techniques to separate cells or particles used either
80complex electrode geometries, more than two electrodes or a set of different voltages, which
81make it more complicated for the integration of such designs in micro-total analysis system.
82Furthermore, to achieve effective particle separation, the channels were initially filled to gener-
83ate an electroosmotic flow before introducing the particle to the channel, which is not possible
84when the design should be used for a POC device.
85From the broad range of different techniques for blood plasma separation, this work
86focuses on the enhancement of cross flow filtration technique due to its adaptability for POC
87use, a summary of achievements in this field is presented in Table I.
88This paper presents a novel, highly efficient blood plasma separator microfluidic chip by tak-
89ing advantage of a cross-flow filtration method combined with a reversible electroosmotic flow to
90prevent RBC accumulation in the entrance of the filtration area. The use of just two simple elec-
91trodes placed in the inlet and the outlet of the microchannel offers advantages such as a straight-
92forward fabrication process and allows the regulation of the flow rate through the voltage. This
93strategy allows the collection of 1ll of blood plasma from a 10-ll fresh human blood sample. In
94the proposed design, two different 50-lm-deep channels are placed in the top part of the micro-
95fluidic design to facilitate the detection and readout of multiple blood parameters.
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96To validate the quality and quantity of the separated plasma and to show its potential as
97clinical tool, the microfluidic chip is combined with lateral flow immunochromatography tech-
98nology to perform two different types of analysis: first, a single test for the qualitative detection
99of the TSH (thyroid-stimulating hormone), and second a blood panel for measuring two indica-
100tors in the diagnosis of myocardial infarction (MI): Cardiac Troponin (cTnI) and Creatine
101Kinase MB (CK-MB). Clearly, a combination of both measurements in the same test device
102increases the efficiency of the diagnosis. The microfluidic chip results are comparable to previ-
103ous commercial lateral flow assays that require (50–100 ll blood and 100–150 ll Buffer
FIG. 1. (a) Schematic diagram of the blood plasma separation microdevice. (b) Detail of the transport channel constriction.
(c) and (d) Electroosmotic flow and RBCs flow directions depending on the electrode polarization.
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104solution) 10 times more sample and a large ratio of blood dilution, which in some applications
105may limit the detection of some substances that are present in very low concentrations.
106According to the results, the combination of the new microfluidic chip with LFA technol-
107ogy fulfills the requirements for a POC device such as short time to result, robustness, user-
108friendly manipulation, portability, flexibility, and low cost per test. Qualitative results can be
109read directly, but for quantification of the analyte, this microfluidics-based lateral flow cartridge
110could be integrated with a direct readout using a smart phone.24
111This paper is organized as follows: the Introduction in Section I. The design principles,
112microfluidic chip fabrication, and experimental setup are explained in the Materials and meth-
113ods in Section II. Experimental results and integration of the plasma separator with analyte
114detection and plasma validation are demonstrated in Results and discussion in Section III, and
115Concluding remarks are presented in Section IV.
116II. MATERIAL AND METHODS
117A. Design principle
118The proposed microfluidic device is based on a microfluidic blood plasma filter developed
119in our group,16,25 see Fig. 1(a).
120In our previous work, Madadi et al.16 the cross-flow filtration and capillarity were used for
121blood plasma separation but the clogging phenomena limited the plasma extracted (0.1ll), see
122Fig. 1(b). In this paper, to address this issue and break the RBCs accumulation and maximize col-
123lected plasma to generate an efficient point of care blood panel device, an electroosmotic flow is
124generated connecting two electrodes placed in the inlet and the outlet, respectively, see Fig. 1(c).
125When a DC electric field is applied between the channel inlet and the channel outlet, the
126ions from the electrolyte form an electric double layer (EDL) over the wall surface. The ions
127from the double layer are attracted to the negative electrode producing an electroosmotic liquid
128flow. The electroosmotic velocity is (EOF)26,27
~Veo ¼ leo~E ¼
emfw
g
~E; (1)
129where E is the magnitude of the electric field, leo is the electroosmotic mobility of the ionic
130fluid, fw is the zeta potential of the wall of microchannel, g is the viscosity, and em is the per-
131mittivity of the fluid. The total electrokinetic velocity (EK) of the suspended RBCs in the fluid
132due to the combined effects of electroosmosis (EO) and electrophoresis (EP) can be expressed as
~VEK ¼ ~VEO  ~VEP ¼ ðleo  lepÞ~E; (2)
133where ~VEK is the total electrokinetic velocity, ~E is electric field strength, leo is the electroos-
134motic mobility, and lep is the electrophoretic mobility.
135The electrophoretic direction of negatively charged particles such as RBCs is from the
136ground to the positive electrode. According to Srivastava et al.,27 RBCs are large with a minor
TABLE I. Cross flow filtration studies for blood plasma separation.
Author Technique Dilution
Extracted plasma
(%)
Purity
(%) Voltage
Crowley and Pizziconi12 Cross flow filtration No 0.3–0.9 N/A …
Chen et al.13 Cross flow filtration 1:1–1:100 N/A 20–95 …
Kang et al.14 Cross flow filtration N/A 5.36 99.9 …
Madadi et al.16 Cross flow filtration-capillarity No 5 99 …
Nakashima et al.22 Cross flow filtration-dielectrophoresis 1:9 6 97 10 V-AC
Mohammadi et al.
(current)
Cross flow filtration-electroosmosis 1:1 10 99 50 V-DC
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137net negative charge, therefore EP mobility is insignificant compared with EO mobility thus lep
138can be neglected. The applied DC electric field creates a net force on the RBCs mainly domi-
139nated by EO flow and particles move from positive to negative electrodes.26,28
140Fig. 1(c) shows how the EOF generates a higher shear rate on the clogged RBCs in the en-
141trance area of the separation zone and consequently controls the RBCs movements.
142In this technique, the direction of this net force is modified by changing the polarity of
143electrodes (reverse EOF), see Figs. 1(c) and 1(d). This reverse DC electric field prevents the
144RBC accumulation at the entrance of the separation area and allows the filtration process to
145proceed till the plasma has reached the test zone of the lateral flow assay test strip. Figs. 2(a)
146and 2(b) show the main dimensions of the proposed design. This extracted blood plasma is col-
147lected in two channels (height, HPC ¼ 50-lm) which are placed 500 lm apart from the transport
148channel in the top part, called plasma collected channels. The width of these plasma collected
149channels increases smoothly from 100-lm (in the filtration area) up to 400-lm at the end where
150the blood plasma is gathered to interface with the lateral flow assay test strips.
151The manufacturing process used in Ref. 16 has been modified to allocate precisely the test
152strip, see Fig. 3 where steps (a) till (d), for Microchannel Integrated Micro-Pillars (MIMP) fab-
153rication are used in Ref. 16 and steps (e) to (h) has been added. Conventional photolithography
154and soft lithography procedures have been utilized to generate top part (PDMS microchannel)
155(Fig. 3(e)) also photolithography and wet chemical method have been used to fabricate the
156down part (glass substrate) (Fig. 3(f)).16 In the test strips, the filtration pad (fiberglass) and the
157absorption pad from the end are removed. After, the test strips are allocated in place (Fig. 3(g))
158and sealed with tape (Fig. 3(h)).
159Fresh blood samples from healthy adults are collected using a lancet from market POCT.
160A 5-ll drop of fresh human whole blood is mixed with 0.5-ll heparin (purchased from Pfizer
161Co., Madrid, Spain) as a standard anticoagulant and 5-ll of phosphate-buffered saline (PBS,
162purchased from Life Technologies S.A., Madrid, Spain). Based on the test strip manufacturer
163(Nal Von Minden) to completely wet the conjugate pad, 5-ll of phosphate-buffered saline is
164added to the LFA strips after the plasma has reached the conjugate pad.
165Two different types of tests are implemented; one measures TSH level (as in Ref. 16) and
166the other is a blood panel for measuring two indicators in the diagnosis of MI, cTnI, and CK-
167MB in the same cartridge.
168The cTnI is a protein found in the cardiac muscle that is released into the blood 4 to 6 h after
169the onset of pain. CK-MB is an enzyme found in the cardiac muscle too, but this is released, 3 to
1708 h after the onset of symptoms, but it lasts up to 72 h while cTnI can be elevated up to 10 days.
171This is a clear example where the use of a microfluidic cartridge that maximizes the amount of
172extracted plasma allows a combination of both measurements and therefore increases the efficiency
173of the diagnosis.
FIG. 2. Design dimensions. (a) Top part. (b) Down part diamond shaped post-array.
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174The separated plasma in both plasma-collected channels is driven to the entrance of the
175test strip. The test strip gold conjugate pad is overlapped with the blood plasma reservoir and is
176sealed with tape, see Figs. 3(g) and 3(h). In the gold conjugate pad, the plasma antigens are
177recognized and bound to the gold-conjugated antibodies and coloring the control line if the test
178works properly and the test band if the test is positive, see Fig. 6(b).
179The appearance of a coloured band at the control region serves as a procedural control,
180indicating that the proper volume of specimen has been added. ImageJ software was employed
181to measure color intensity of both commercial LFA strip and microfluidic device coloured
182band. Two dimensional profile of color intensity along considered rectangular was created in
183Analyze /plot profile module. (The Y-axis the vertically averaged pixel intensity and X-axis
184present the horizontal distance through the selection.)
185III. RESULTS AND DISCUSSION
186Fig. 4(a) (Multimedia view) shows the device before introducing the 5-ll droplet of human
187blood sample into the inlet port of the transport channel, and a 5-ll droplet of blood sample is
188dropped into the outlet to avoid a hydrostatic pressure difference in the main channel. The
189blood sample is first drawn into the microdevice, due to the capillary forces.
FIG. 3. Schematic view of the microdevicegure fabrication. (a)–(d) MIMP filtration channel manufacturing steps, (e) the
microdevice top part with the test window, the channel inlet, and the channel outlet (PDMS), (f) the microdevice down part
(glass), (g) bonding of both parts, and (h) the complete microdevice with the test strip covered with tape.AQ3
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190The separation process starts as soon as the blood flows in the transport channel and arrives
191in the MIMP filtration channel in the down part. The capillary forces are not enough to fill the
19250-lm-deep plasma-collected channels. Therefore, to increase the volume of extracted plasma
193after 2 min, 50 V are applied between the channel inlet and the channel outlet in a 22-mm long
194microchannel, see Fig. 4(b) (Multimedia view).
195The applied electric field creates an EO flow from the inlet to the outlet (positives to nega-
196tive electrode) that speeds up the filling process of the plasma-collected channels; see Figs. 4(c)
197and 4(d) (Multimedia view).
198The results of the numerical simulation of the flow direction created by the electric field
199and also a video clip of the performance of the blood plasma separation microdevice are pro-
200vided in supplementary material Figs. S-1 and S-2 (Ref. 29) and movie S1.29
201Normally, RBCs clogging is inevitable in the separation zone of blood microfilter, the ve-
202locity of blood is decreased in the transport channel which leads to an accumulation of cells in
203the entrance of the separation area, see Fig. 4(b).
204In order to break the accumulation of RBCs and avoid clogging in the entrance of the fil-
205tration area, the direction of the electric field is optimally changed every 30 s during 5 s (outlet
206to the inlet). It should be noted that, based on the experimental result, applying EOF more than
20730 s and reverse EOF less than 5 s could permanently clog the MIMP while employing EOF
208less than 30 s and reverse EOF more than 5 could reduce the amount of separated plasma.
209Fig. 5(a) (Multimedia view) shows the direction of EO flow in the transport, MIMP channels,
210and how the RBCs clog the entrance to the MIMP filtration area (30 s). Fig. 5(b) (Multimedia view)
211shows the backward generated electroosmotic flow when the polarity is changed. This flow pushes
212the RBCs away from the entrance of the MIMP and breaks the RBCs clogging. Based on our experi-
213mental result, the electroosmotic mobility of PDMS and blood is leo ðPDMSÞ ¼ 2:8 108 m
2
V s
 
214which generates almost 60–80 lm/s electroosmotic velocity in transport channel. The complete open-
215ing of the filtration entrance is shown in Fig. 5(c) (Multimedia view). A video clip of the breaking per-
216formance of RBCs clogging is presented in the supplementary material movie S2.29
FIG. 4. Microdevice performance. (a) Initial empty channel, (b) filling the transport channel after applying voltage and
plasma separation, (c) filling the plasma-collected channel, and (d) end of the plasma-collected channel. (Multimedia view)
[URL: http://dx.doi.org/10.1063/1.4930865.1]
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217If the plasma purity is defined as
Purity ¼ 1 CP
CM
; (3)
218where CP is the number of RBC in the plasma collected channel, and CM is the number of
219RBC in the main channel. ImageJ is used to compare the number of RBCs in the region marked
220in Figs. 4(b) and 4(d). The purity calculated from Equation (3) of the extracted blood plasma
221from whole blood in the plasma channel topology is more than 99% (by considering 106 RBCs/
222ll in whole human blood, less than 5 103 RBCs in whole separated plasma).
223Calculating the total area filled with plasma, around 1 ll of blood plasma, is successfully
224separated from 10 ll of fresh blood sample in all the tests. According to the results, the plasma
225collected channels are filled in 8–10 min with a purity of more than 99%. The results of five
226fabricated devices are summarized in Table II, showing the average and standard deviation of
227the recorded data; see supplementary material Table S-1.29
228A. TSH test
229All components of the test strip are shown in Fig. 6(a), notice that the filtration pad and
230absorption pad have been removed in order integrate the lateral flow assay in the microfluidic
231chip. The separated plasma reaches to the conjugated pad after 8 min, and the chromatography
FIG. 5. RBC clogging and breakage procedure. (a) The RBCs clog the entrance of the filtration area. (b) Opening of the en-
trance of the filtration area using reverse EO flow. (c) The entrance is opened after 5 s. (Multimedia view) [URL: http://
dx.doi.org/10.1063/1.4930865.2]
TABLE II. Average amount of separated plasma, time, and purity.
Microchip Blood sample volume Volume of the extracted plasma Time (min) Purity (%)
Reciprocating electroosmotic 10ll 16 .01ll 8–10 >99
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232process is started. Five test devices are tested; a colored line appears in the control section of
233the test strip in average 186 2 min after dropping the blood droplet. The schematic view of the
234test strip is shown in Fig. 6(b). Fig. 7(a) shows a picture of the coloured line in the control sec-
235tion from the microfluidic chip compared to the standard NADAL
VR
TSH test. It should be high-
236lighted that the microfluidic chip is shown from the backside view, since the test strip is rotated
237in the implementation process; see Fig. 3(h).
238For the evaluation of the quality of the obtained plasma and the repeatability of the results,
239the color intensity of the results line of the TSH test is measured using ImageJ software.
FIG. 6. (a) All components of TSH test strip and (b) the test strip without filtration pad and the schematic view of microde-
vice with the test strip.
FIG. 7. (a) The results of the TSH test using in the microfluidic chip and LFA strip. (b) The color intensity of the results of
the TSH test using the microfluidic chip and the LFA strip. (c) and (d) The results of the myocardial infarction tests using
the microfluidic chip and cTnI and CKMB LFA strips.
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240Fig. 7(b) shows that the average color intensity of the commercial LFA test strip, which is
241equivalent to the results obtained with the microfluidic chip.
242B. Myocardial infarction test (MI blood panel)
243The capability of the presented microdevice for separating and gathering blood plasma
244within more than one plasma-collected channel paves the way for multiplex blood analysis
245simultaneously in the same device. In order to implement myocardial infarction test, half test
246strip of cTnI and CK-MB has been placed in test location of the microfluidic device.
247Five test devices have been tested; the average time for the colored line to appear is
248206 2 min after dropping the blood droplet. The hybrid microfluidic device with cTnI and CK,
249also commercial LFA cTnI and CK-MB tests, are shown in Figs. 7(c) and 7(d).
250Table III and Fig. 7 show that the results obtained from the proposed device and commer-
251cial LFA test strip are equivalent (Fig. 7(b)) but the required sample is 5 times less.
252During all the experimental procedure, the voltage is kept below 50 V between the inlet
253and the outlet of the 22-mm-long channel, which generates an electric field that cannot lyse the
254cells,30,31 see supplementary material Fig. S-1. But the quality of the obtained plasma was also
255analyzed using Image J software.
256The variation of the color intensity is measured over a 160-lm line region 20 s and 8 min
257after the beginning of the test in the MIMP filtration area. The same procedure is repeated for
258the blood sample in the transport channel, see supplementary material Fig. S-3.29
259The measurement shows that the variation of plasma color intensity is negligible (less than
2601%) during the experiment (8 min), therefore the plasma is separated without haemolysis.
261IV. CONCLUSION
262A novel microfluidic chip for blood plasma separation, which combines microfluidics with
263conventional lateral flow immunochromatography to extract enough plasma to perform a blood
264panel in a simple and portable device, is designed and fabricated in the present study. The
265microfluidic chip design is a combination of cross-flow filtration with a reversible electroos-
266motic flow that with only 50 V prevents clogging at the filter entrance and separates more than
2671-ll of plasma of high purity (more than 99%) in a reasonable time (5 to 8 min). The main
268advantage of this design is its portability and the small amount of sample required (a single
269droplet 10 ll). The potential as clinical tool has been proved combining with lateral flow
270immunochromatography technology to perform a qualitative detection of the TSH and a blood
271panel for measuring cardiac Troponin and Creatine Kinase MB. The results obtained from the
272microfluidic system are comparable to previous commercial lateral flow assays that required
273more sample for implementing less tests. According to the results, the combination of the new
274microfluidic chip with LFA technology fulfills the requirements for a POC device such as
275robustness, user-friendly manipulation, and simple handling, since the blood sample can be ana-
276lyzed directly. For a quantification of the analyte, this microfluidics-based lateral flow cartridge
277can be easily integrated to a readout device, for instance a smart phone.
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TABLE III. Required blood sample volume for LFA test strip and microfluidic device.
Microchip Blood sample volume (ll) Buffer solution (ll)
Microfluidic chip  10  10
LFA strip  50–100  100–150
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